Excessive sympathoactivation and deteriorated heart function after myocardial infarction in male ghrelin knockout mice

Endocrinology

Volumn 154, Issue 5, 2013, Pages 1854-1863

  Mao, Yuanjie ^a   Tokudome, Takeshi ^a   Otani, Kentaro ^a   Kishimoto, Ichiro ^a   Miyazato, Mikiya ^a   Kangawa, Kenji ^a  

^a NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; GHRELIN; METOPROLOL; NORADRENALIN; RECOMBINANT GHRELIN; RECOMBINANT HORMONE; UNCLASSIFIED DRUG;

ACUTE HEART INFARCTION; ADRENALIN BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; CORONARY ARTERY LIGATION; HEART FAILURE; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE ENDSYSTOLIC VOLUME; HEART RATE VARIABILITY; HEART STROKE VOLUME; LEFT CORONARY ARTERY LIGATION; LUNG WEIGHT; MALE; MORTALITY; MOUSE; NONHUMAN; NORADRENALIN BLOOD LEVEL; PRIORITY JOURNAL; PROTEIN FUNCTION; SURVIVAL RATE; SYMPATHETIC ACTIVATION; SYMPATHETIC FUNCTION; TELEMETRY; TIBIA; WILD TYPE;

ANIMALS; BLOOD PRESSURE; GHRELIN; HEART; HEART FAILURE; HEART RATE; MALE; METOPROLOL; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MYOCARDIAL INFARCTION; SURVIVAL ANALYSIS; SYMPATHETIC NERVOUS SYSTEM; SYMPATHOLYTICS;

EID: 84876772269     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2012-2132     Document Type: Article

References (30)

1. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999;402:656-660.
2. Gnanapavan S, Kola B, Bustin SA, et al. The tissue distribution of the mRNA of ghrelin and subtypes of its receptor, GHS-R, in humans. J Clin Endocrinol Metab. 2002;87:2988-2991.
3. Nagaya N, Uematsu M, Kojima M, et al. Chronic administration of ghrelin improves left ventricular dysfunction and attenuates development of cardiac cachexia in rats with heart failure. Circulation. 2001;104:1430-1435.
4. Nagaya N, Moriya J, Yasumura Y, et al. Effects of ghrelin administration on left ventricular function, exercise capacity, and muscle wasting in patients with chronic heart failure. Circulation. 2004; 110:3674-3679.
5. Soeki T, Kishimoto I, Schwenke DO, et al. Ghrelin suppresses cardiac sympathetic activity and prevents early left ventricular remodeling in rats with myocardial infarction. Am J Physiol Heart Circ Physiol. 2008;294:H426-H432.
6. Schwenke DO, Tokudome T, Kishimoto I, et al. Early ghrelin treatment after myocardial infarction prevents an increase in cardiac sympathetic tone and reduces mortality. Endocrinology. 2008;149: 5172-5176.
7. Matsumura K, Tsuchihashi T, Fujii K, Abe I, Iida M. Central ghrelin modulates sympathetic activity in conscious rabbits. Hypertension. 2002;40:694-699.
8. Lin Y, Matsumura K, Fukuhara M, Kagiyama S, Fujii K, Iida M. Ghrelin acts at the nucleus of the solitary tract to decrease arterial pressure in rats. Hypertension. 2004;43:977-982.
9. Mao Y, Tokudome T, Otani K, et al. Ghrelin prevents incidence of malignant arrhythmia after acute myocardial infarction through vagal afferent nerves. Endocrinology. 2012;153:3426-3434.
10. Rossow CF, Minami E, Chase EG, Murry CE, Santana LF. NFATc3-induced reductions in voltage-gated K-currents after myocardial infarction. Circ Res. 2004;94:1340-1350.
11. Kar S, Gao L, Belatti DA, Curry PL, Zucker IH. Central angiotensin (1-7) enhances baroreflex gain in conscious rabbits with heart failure. Hypertension. 2011;58:627-634.
12. Dornonville de la Cour C, Lindqvist A, Egecioglu E, et al. Ghrelin treatment reverses the reduction in weight gain and body fat in gastrectomised mice. Gut. 2005;54:907-913.
13. Pacher P, Nagayama T, Mukhopadhyay P, Bátkai S, Kass DA. Measurement of cardiac function using pressure-volume conductance catheter technique in mice and rats. Nat Protoc. 2008;3:1422-1434.
14. Thireau J, Zhang BL, Poisson D, Babuty D. Heart rate variability in mice: a theoretical and practical guide. Exp Physiol. 2008;93:83-94.
15. Kinoshita H, Kuwahara K, Takano M, et al. T-type Ca2-channel blockade prevents sudden death in mice with heart failure. Circulation. 2009;120:743-752.
16. Thayer JF, Yamamoto SS, Brosschot JF. The relationship of autonomic imbalance, heart rate variability and cardiovascular disease risk factors. Int J Cardiol. 2010;141:122-131.
17. Jardine DL, Charles CJ, Ashton RK, et al. Increased cardiac sympathetic nerve activity following acute myocardial infarction in a sheep model. J Physiol. 2005;565(Pt 1):325-333.
18. Sutton MG, Sharpe N. Left ventricular remodeling after myocardial infarction: pathophysiology and therapy. Circulation. 2000;101: 2981-2988.
19. Udelson JE, Patten RD, Konstam MA. New concepts in post-infarction ventricular remodeling. Rev Cardiovasc Med. 2003;4(suppl 3):S3-S12.
20. Kobashi M, Yanagihara M, Fujita M, Mitoh Y, Matsuo R. Fourth ventricular administration of ghrelin induces relaxation of the proximal stomach in the rat. Am J Physiol Regul Integr Comp Physiol. 2009;296:R217-R223.
21. Shimizu S, Akiyama T, Kawada T, et al. Centrally administered ghrelin activates cardiac vagal nerve in anesthetized rabbits. Auton Neurosci. 2011;162:60-65.
22. Yasuda T, Masaki T, Kakuma T, Yoshimatsu H. Centrally administered ghrelin suppresses sympathetic nerve activity in brown adipose tissue of rats. Neurosci Lett. 2003;349:75-78.
23. Date Y, Murakami N, Toshinai K, et al. The role of the gastric afferent vagal nerve in ghrelin-induced feeding and growth hormone secretion in rats. Gastroenterology. 2002;123:1120-1128.
24. Cui RJ, Li X, Appleyard SM. Ghrelin inhibits visceral afferent activation of catecholamine neurons in the solitary tract nucleus. J Neurosci. 2011;31:3484-3492.
25. Sato T, Nakashima Y, Nakamura Y, Ida T, Kojima M. Continuous antagonism of the ghrelin receptor results in early induction of saltsensitive hypertension. J Mol Neurosci. 2011;43:193-199.
26. Baldanzi G, Filigheddu N, Cutrupi S, et al. Ghrelin and des-Acyl ghrelin inhibit cell death in cardiomyocytes and endothelial cells through ERK1/2 and PI 3-kinase/AKT. J Cell Biol. 2002;159:1029-1037.
27. Iglesias MJ, Piñeiro R, Blanco M, et al. Growth hormone releasing peptide (ghrelin) is synthesized and secreted by cardiomyocytes. Cardiovasc Res. 2004;62:481-488.
28. Chang L, Ren Y, Liu X, et al. Protective effects of ghrelin on ischemia/ reperfusion injury in the isolated rat heart. J Cardiovasc Pharmacol. 2004;43:165-170.
29. Strassburg S, Anker SD. Metabolic and immunologic derangements in cardiac cachexia: where to from here? Heart Fail Rev. 2006;11: 57-64.
30. Nagaya N, Uematsu M, Kojima M, et al. Elevated circulating level of ghrelin in cachexia associated with chronic heart failure: relationships between ghrelin and anabolic/catabolic factors. Circulation. 2001;104:2034-2038.